BRCA1 and myxofibrosarcoma: Within the STS cohort, oncogenic BRCA1 mutations were identified in patients diagnosed with leiomyosarcoma (n=8), myxofibrosarcoma (n=3), undifferentiated pleomorphic sarcoma (n=3), sarcoma NOS (n=2), inflammatory myofibroblastic tumor (n=1), Ewing sarcoma of soft tissue (n=1), pleomorphic liposarcoma (n=1), solitary fibrous tumor (n=1), synovial sarcoma (n=1), dedifferentiated liposarcoma (n=1), and spindle cell rhabdomyosarcoma (n=1).